• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Teradyne Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket

    4/25/24 6:12:22 AM ET
    $AIRE
    $ASTI
    $BOF
    $BPTS
    Real Estate
    Finance
    Semiconductors
    Technology
    Get the next $AIRE alert in real time by email

    Shares of Teradyne, Inc. (NASDAQ:TER) rose sharply in today's pre-market trading after the company posted upbeat first-quarter results and issued strong second-quarter forecast.

    Teradyne posted adjusted earnings of 51 cents per share, beating market estimates of 33 cents per share. The company's quarterly sales came in at $599.819 million versus expectations of $566.310 million, according to data from Benzinga Pro.

    Teradyne shares jumped 8.4% to $109.20 in pre-market trading.

    Here are some other stocks moving in pre-market trading.

    Gainers

    • Intelligent Living Application Group Inc. (NASDAQ:ILAG) shares gained 57.3% to $0.8496 in pre-market trading after gaining over 12% on Wednesday.
    • reAlpha Tech Corp. (NASDAQ:AIRE) gained 31.8% to $1.53 in pre-market trading after jumping 93% on Wednesday.
    • Nuwellis, Inc. (NASDAQ:NUWE) climbed 25.9% to $0.3174 in pre-market trading after dipping 15% on Wednesday.
    • Cidara Therapeutics, Inc. (NASDAQ:CDTX) gained 23% to $15.11 in pre-market trading after the company announced the divestiture of rezafungin to Mundipharma*, reacquired global development and commercial rights to CD388 and announced $240 million in private placement financing.
    • ImmunityBio, Inc. (NASDAQ:IBRX) rose 15.4% to $5.56 in today's pre-market trading after the company reported results of Anktiva combined with checkpoint inhibitors in non-small cell lung cancer.
    • Hitek Global Inc. (NASDAQ:HKIT) shares gained 13.3% to $1.53 in pre-market trading.
    • Serve Robotics Inc (NASDAQ:SERV) shares gained 9.6% to $3.09 in pre-market trading after dipping 11% on Wednesday.
    • Ascent Solar Technologies, Inc. (NASDAQ:ASTI) shares rose 9.1% to $0.099 in pre-market trading after falling 11% on Wednesday.
    • TAL Education Group (NYSE:TAL) shares rose 9.1% to $13.38 in pre-market trading following upbeat quarterly results.

    Losers

    • Biophytis S.A. (NASDAQ:BPTS) fell 36% to $6.08 in pre-market trading. Biophytis announced transfer of ADSs to OTC Market.
    • Chicken Soup for the Soul Entertainment, Inc. (NASDAQ:CSSE) declined 22.2% to $0.3307 in pre-market trading. Chicken Soup For The Soul Entertainment received delinquency letter from the Nasdaq.
    • Zapp Electric Vehicles Group Limited (NASDAQ:ZAPP) fell 18.7% to $3.21 in pre-market trading after dipping 15% on Wednesday.
    • ESGL Holdings Limited (NASDAQ:ESGL) shares fell 14.5% to $0.54 in pre-market trading.
    • iSun, Inc. (NASDAQ:ISUN) fell 13.5% to $0.0812 in pre-market trading. iSun shares dipped 38% on Wednesday after the company announced a reverse stock split.
    • Meta Platforms, Inc. (NASDAQ:META) shares declined 12.9% to $429.25 in pre-market trading after reporting first-quarter results.
    • BranchOut Food Inc. (NASDAQ:BOF) fell 10.1% to $1.87 pre-market trading. BranchOut Food shares jumped 82% on Wednesday after the company announced it has expanded its existing relationship with the nation’s largest retailer, which brings the total annualized value of commitments from the retailer to over $8 million.
    • International Business Machines Corporation (NYSE:IBM) fell 8.4% to $168.73 in pre-market trading after the company reported mixed first-quarter financial results. The company also announced it will acquire HashiCorp.
    • Vista Energy, S.A.B. de C.V. (NYSE:VIST) shares fell 8.3% to $39.80 in pre-market trading after the company reported worse-than-expected first-quarter financial results.
    • Snap Inc. (NYSE:SNAP) fell 5% to $10.53 pre-market trading.

    Now Read This: Top 3 Industrials Stocks That Are Set To Fly In April

    Get the next $AIRE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIRE
    $ASTI
    $BOF
    $BPTS

    CompanyDatePrice TargetRatingAnalyst
    Meta Platforms Inc.
    $META
    3/5/2026Buy → Neutral
    Arete
    Meta Platforms Inc.
    $META
    3/5/2026Hold → Buy
    Erste Group
    International Business Machines Corporation
    $IBM
    2/25/2026$236.00Sell → Neutral
    UBS
    Meta Platforms Inc.
    $META
    2/23/2026$849.00 → $856.00Overweight
    Wells Fargo
    International Business Machines Corporation
    $IBM
    2/18/2026Buy → Hold
    Erste Group
    Snap Inc.
    $SNAP
    2/10/2026$7.30Neutral → Buy
    Arete
    Snap Inc.
    $SNAP
    2/6/2026$5.50Sell → Hold
    Stifel
    Snap Inc.
    $SNAP
    2/5/2026$10.00Neutral → Buy
    BofA Securities
    More analyst ratings

    $AIRE
    $ASTI
    $BOF
    $BPTS
    SEC Filings

    View All

    SEC Form DEFA14A filed by International Business Machines Corporation

    DEFA14A - INTERNATIONAL BUSINESS MACHINES CORP (0000051143) (Filer)

    3/10/26 4:22:49 PM ET
    $IBM
    Computer Manufacturing
    Technology

    SEC Form DEF 14A filed by International Business Machines Corporation

    DEF 14A - INTERNATIONAL BUSINESS MACHINES CORP (0000051143) (Filer)

    3/10/26 4:21:45 PM ET
    $IBM
    Computer Manufacturing
    Technology

    SEC Form 6-K filed by ESGL Holdings Limited

    6-K - ESGL Holdings Ltd (0001957538) (Filer)

    3/10/26 4:15:15 PM ET
    $ESGL
    Environmental Services
    Utilities

    $AIRE
    $ASTI
    $BOF
    $BPTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel Dunn Evan sold $5,079 worth of shares (538 units at $9.44), decreasing direct ownership by 0.27% to 202,294 units (SEC Form 4)

    4 - Serve Robotics Inc. /DE/ (0001832483) (Issuer)

    3/9/26 5:04:45 PM ET
    $SERV
    Industrial Specialties
    Consumer Discretionary

    Director Johnson Mercedes sold $187,000 worth of shares (625 units at $299.20), decreasing direct ownership by 8% to 6,988 units (SEC Form 4)

    4 - TERADYNE, INC (0000097210) (Issuer)

    3/6/26 5:50:33 PM ET
    $TER
    Electrical Products
    Industrials

    SEC Form 3 filed by new insider Antony Prabhu

    3 - reAlpha Tech Corp. (0001859199) (Issuer)

    3/6/26 5:25:14 PM ET
    $AIRE
    Real Estate
    Finance

    $AIRE
    $ASTI
    $BOF
    $BPTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The Encryption Deadline Wall Street Hasn't Priced In

    Issued on behalf of Quantum Secure Encryption Corp.VANCOUVER, BC, March 10, 2026 /CNW/ -- USANewsGroup.com News Commentary -- Every federal agency in the United States has been ordered to adopt quantum-resistant encryption by January 2027, and CISA now requires that procurement across designated technology categories reflect that timeline immediately[1]. The mandate is accelerating an industry already in motion: the global quantum technology market is projected to reach US$7.66 billion by 2031, a 22.6% CAGR driven by surging demand for quantum-resilient infrastructure[2]. Companies building for that deadline include Quantum Secure Encryption Corp. (CSE:QSE) (OTCQB:QSEGF) (FSE: VN8), Rigetti

    3/10/26 12:34:00 PM ET
    $IBM
    $INFQ
    $LAES
    Computer Manufacturing
    Technology
    EDP Services
    Semiconductors

    Serve Robotics' MJ Burk Chun Named a Top Female Founder by Inc.

    As co-founder and VP of product and design, MJ Burk Chun has been instrumental in scaling Serve's robots across the U.S. while fostering a culture of creativity and inclusion throughout the companyMJ joins Inc.'s annual Female Founders list, which honors the nation's most innovative women entrepreneurs and counts trailblazers like Billie Jean King and Serena Williams among its past honorees SAN FRANCISCO, March 10, 2026 (GLOBE NEWSWIRE) -- Serve Robotics Inc. (NASDAQ:SERV), a leading autonomous robotics company, today announced that MJ Burk Chun, vice president of product and design, has been named to Inc.'s 2026 Female Founders 500, an annual list honoring the most dynamic business leade

    3/10/26 11:51:27 AM ET
    $SERV
    Industrial Specialties
    Consumer Discretionary

    IBM and Lam Research Announce Collaboration to Advance Sub-1nm Logic Scaling

    Agreement includes development of novel materials, advanced processes, and High NA EUV lithography techniques to enable future logic nodesALBANY, N.Y. and FREMONT, Calif., March 10, 2026 /PRNewswire/ -- IBM (NYSE: IBM) and Lam Research Corp. (NASDAQ: LRCX) today announced a collaboration aimed at developing new processes and materials to support sub-1nm logic scaling. Building on a long record of successful partnerships, the new agreement will focus on the joint development of novel materials, fabrication processes, and High NA EUV lithography processes to advance IBM's logic scaling roadmap.IBM and Lam have collaborated for more than a decade to advance logic fabrication, notably enabling e

    3/10/26 9:00:00 AM ET
    $IBM
    $LRCX
    Computer Manufacturing
    Technology
    Industrial Machinery/Components

    $AIRE
    $ASTI
    $BOF
    $BPTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Howard Michelle J bought $11,891 worth of shares (50 units at $237.83), increasing direct ownership by 35% to 194 units (SEC Form 4)

    4 - INTERNATIONAL BUSINESS MACHINES CORP (0000051143) (Issuer)

    2/25/26 4:34:02 PM ET
    $IBM
    Computer Manufacturing
    Technology

    Director Miebach Michael bought $101,264 worth of shares (434 units at $233.33) (SEC Form 4)

    4 - INTERNATIONAL BUSINESS MACHINES CORP (0000051143) (Issuer)

    2/25/26 4:32:44 PM ET
    $IBM
    Computer Manufacturing
    Technology

    Director Farr David N bought $304,000 worth of shares (1,000 units at $304.00), increasing direct ownership by 12% to 9,258 units (SEC Form 4)

    4 - INTERNATIONAL BUSINESS MACHINES CORP (0000051143) (Issuer)

    1/30/26 5:35:34 PM ET
    $IBM
    Computer Manufacturing
    Technology

    $AIRE
    $ASTI
    $BOF
    $BPTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Meta Platforms downgraded by Arete

    Arete downgraded Meta Platforms from Buy to Neutral

    3/5/26 8:27:42 AM ET
    $META
    Computer Software: Programming Data Processing
    Technology

    Meta Platforms upgraded by Erste Group

    Erste Group upgraded Meta Platforms from Hold to Buy

    3/5/26 8:23:30 AM ET
    $META
    Computer Software: Programming Data Processing
    Technology

    IBM upgraded by UBS with a new price target

    UBS upgraded IBM from Sell to Neutral and set a new price target of $236.00

    2/25/26 7:38:09 AM ET
    $IBM
    Computer Manufacturing
    Technology

    $AIRE
    $ASTI
    $BOF
    $BPTS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 7, 2024 - FDA Roundup: June 7, 2024

    For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

    6/7/24 3:46:22 PM ET
    $GERN
    $SRAX
    $SNAP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Advertising
    Consumer Discretionary

    March 22, 2024 - FDA Roundup: March 22, 2024

    For Immediate Release: March 22, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued an emergency use authorization for Pemgarda (pemivibart) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents (12 years of age and older weighing at least 40 kilograms [about 88 pounds]).  Pemgarda is

    3/22/24 5:02:42 PM ET
    $SNAP
    $SRAX
    Computer Software: Programming Data Processing
    Technology
    Advertising
    Consumer Discretionary

    November 9, 2023 - FDA Approves First Treatment for Patients with Rare Inherited Blood Clotting Disorder

    For Immediate Release: November 09, 2023 Today, the U.S. Food and Drug Administration approved Adzynma, the first recombinant (genetically engineered) protein product indicated for prophylactic (preventive) or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), a rare and life-threatening blood clotting disorder. “The FDA remains

    11/9/23 2:30:20 PM ET
    $SRAX
    $SNAP
    Advertising
    Consumer Discretionary
    Computer Software: Programming Data Processing
    Technology

    $AIRE
    $ASTI
    $BOF
    $BPTS
    Leadership Updates

    Live Leadership Updates

    View All

    Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy

    MINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of Stuart L. Goldstein, MD, FASN as Director of Clinical Strategy. Dr. Goldstein is internationally recognized as a pioneer in pediatric nephrology and critical care medicine. He serves as Director of the Center for Acute Care Nephrology, holds the Clark D. West Endowed Chair in Pediatric Nephrology at Cincinnati Children's Hospital Medical Center and is Professor of Pediatrics at the University of Cincinnati College of Medicine. His work has helped define the modern understand

    3/5/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    reAlpha Tech Corp. Appoints Thomas Kutzman as Chief Financial Officer to Support Growth Strategy

    DUBLIN, Ohio, Feb. 27, 2026 (GLOBE NEWSWIRE) -- reAlpha Tech Corp. (NASDAQ:AIRE) (the "Company" or "reAlpha"), an AI-powered real estate technology company, today announced the appointment of Thomas Kutzman as Chief Financial Officer, effective February 25, 2026. Mr. Kutzman succeeds Piyush Phadke and will oversee the Company's financial operations, capital strategy, and key corporate functions such as human resources and legal, reporting directly to Chief Executive Officer Mike Logozzo. Kutzman brings more than 12 years of financial markets experience to the role. Prior to co-founding Prevu, he held investment and trading roles at SAC Capital, JPMorgan, Citi, and Jabre Capital Partners,

    2/27/26 8:30:00 AM ET
    $AIRE
    Real Estate
    Finance

    Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors

    MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The appointments strengthen the Company's board with complementary expertise in public company leadership, capital markets, and medical device commercialization. "These appointments reflect our continued focus on operational discipline and long-term value creation," said John Erb, President and CEO of Nuwellis. "Marty has led multiple medical device organizations through scali

    2/26/26 8:00:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AIRE
    $ASTI
    $BOF
    $BPTS
    Financials

    Live finance-specific insights

    View All

    Nuwellis, Inc. Announces Fourth Quarter and Full Year 2025 Financial Results

    MINNEAPOLIS, March 10, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Recent Highlights: Fourth quarter revenue of $2.4 million, a 4% increase compared to the prior-year quarter and 9% increase sequentially.208% increase in U.S. console sales in Q4 versus prior year quarter.Heart Failure revenue increased 48% and Pediatrics increased 16% year-over-year in Q4.Gross margin of 68.2% in Q4, compared to 58.4% in the prior-year quarter.Closed a $5.0 million private p

    3/10/26 8:15:00 AM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

    ImmunityBio, Inc. ((IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across the company's clinical trial pipeline, and to review financial results for the year ended December 31, 2025. Conference Call Details The conference call will begin at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on Tuesday, March 3, 2026. Interested parties may access the conference call through our Investor Relations website, ir.immunitybio.com, under Company — Events & Presentations. Alternatively, individuals can access the call by dialing 1-844-539-3703 or 1-412-652-1273 (internationally).

    2/27/26 7:30:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Serve Robotics to Report Fourth Quarter 2025 Financial Results, Host Conference Call and Webcast on March 11

    SAN FRANCISCO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Serve Robotics Inc. ("Serve") (NASDAQ:SERV), a leading autonomous robotics company, today announced that it will report its 2025 fourth quarter financial results before the opening of regular trading on Wednesday, March 11, 2026. The company will host a conference call and webcast to review the results on the same day. Conference Call and Webcast InformationCompany management will host a conference call at 8 a.m. PT / 11 a.m. ET. A live audio webcast will be available at investors.serverobotics.com and a replay will be available at the same location. Analysts and investors who wish to submit questions to management may send an email to inv

    2/25/26 7:30:00 AM ET
    $SERV
    Industrial Specialties
    Consumer Discretionary

    $AIRE
    $ASTI
    $BOF
    $BPTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by BranchOut Food Inc.

    SC 13D/A - BranchOut Food Inc. (0001962481) (Subject)

    12/11/24 5:14:42 PM ET
    $BOF
    Packaged Foods
    Consumer Staples

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/9/24 5:37:15 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Cidara Therapeutics Inc.

    SC 13G - Cidara Therapeutics, Inc. (0001610618) (Subject)

    12/4/24 4:15:14 PM ET
    $CDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care